Supernus Pharmaceuticals, Inc. SUPN
42.66
(0.63)
(1.46%)
as of 25 Sep
- Market cap
- $2.5B
- P/E
- 0.0×
Follow SUPN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
3.25 | 3.84 | 3.90 | 3.97 | |
P/FCF ratio |
161.27 | 37.09 | 63.18 | 39.07 | |
P/Operating CF |
(561.50) | 44.79 | 141.26 | (43.83) | |
P/B ratio |
2.62 | 2.77 | 2.64 | 2.57 | |
Price to Tangible BV |
6.11 | 7.33 | 7.64 | 8.80 | |
EV/Sales |
2.85 | 3.40 | 3.53 | 3.61 | |
EV/EBITDA |
0.00 | 72.65 | 91.49 | 53.85 | |
EV/Operating CF |
119.07 | 31.68 | 53.64 | 34.27 | |
EV/FCF |
141.56 | 32.83 | 57.17 | 35.62 | |
Quick Ratio |
1.68 | 1.51 | 1.47 | 1.37 | |
Current Ratio |
2.08 | 1.96 | 1.90 | 1.80 | |
Net Debt/EBITDA |
11.43 | (21.82) | (14.31) | 7.74 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.59 | 0.55 | 0.51 | 0.49 | |
Operating CF/Net income |
0.08 | (29.01) | (4.84) | 1.37 | |
Capex/Depreciation |
(0.02) | 0.00 | (0.02) | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
13.45% | 18.99% | 13.15% | 15.29% | |
Selling, General and Administrative Expense of Revenue |
61.01% | 60.26% | 57.85% | 93.53% | |
Intangible Assets out of Total Assets |
0.41 | 0.45 | 0.48 | 0.52 | |
Share Based Compensation of Revenue |
3.94% | 4.08% | 4.56% | 4.07% | |
Graham Net Nets |
0.12 | 0.10 | 0.09 | 0.08 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.13%) | (0.99%) | (1.37%) | (0.69%) | |
Free Cash Flow Yield |
0.62% | 2.70% | 1.58% | 2.56% | |
Revenue per Share |
3.77 | 3.60 | 3.75 | 3.40 | |
Operating CF per Share |
(0.08) | 1.15 | 0.35 | (1.09) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.09) | 1.15 | 0.34 | (1.09) | |
Cash per Share |
6.41 | 6.67 | 5.47 | 4.97 | |
Shareholders Equity per Share |
17.76 | 18.68 | 18.81 | 18.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
17.76 | 18.68 | 18.81 | 18.56 | |
Free Cash Flow |
(5.38) | 66.52 | 19.43 | (61.79) | |
Working Capital |
376.12 | 357.65 | 306.01 | 263.26 | |
Capital Expenditures |
(0.57) | — | (0.43) | (0.13) | |
Net Current Asset Value |
326.61 | 307.66 | 253.25 | 223.80 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(26.65%) | (1.10%) | (1.94%) | (23.49%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
176.24 | 163.91 | 164.94 | 158.33 | |
Average Payables |
93.10 | 89.07 | 92.08 | 92.21 | |
Average Inventory |
63.97 | 68.24 | 68.34 | 71.69 | |
Average Assets |
1,405.26 | 1,424.01 | 1,410.36 | 1,381.23 | |
Average Common Equity |
1,047.56 | 1,053.76 | 1,048.72 | 1,028.41 |
Columns are period end dates